Get the Stockscreener App
968.49
0.54%
5.16
After Hours:
965.76
-2.73
-0.28%
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $968.49, with a volume of 3.13M.
It is up +0.54% in the last 24 hours and up +3.52% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$963.33
Open:
$960
24h Volume:
3.13M
Relative Volume:
0.97
Market Cap:
$866.62B
Revenue:
$72.25B
Net Income/Loss:
$25.28B
P/E Ratio:
34.86
EPS:
27.781
Net Cash Flow:
$10.37B
1W Performance:
+11.54%
1M Performance:
+3.52%
6M Performance:
+6.80%
1Y Performance:
+17.59%
1-Day Range:
$951.76
$974.22
1-Week Range:
$850.51
$984.45
52-Week Range:
$623.78
$1,133.95
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, AZN, MRK
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
968.49 | 862.01B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
224.20 | 546.90B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
208.16 | 365.43B | 62.82B | 3.62B | 17.82B | 2.0331 |
AZN
Astrazeneca Plc
|
183.46 | 286.50B | 60.48B | 10.40B | 8.05B | 3.3297 |
MRK
Merck Co Inc
|
113.11 | 277.02B | 65.59B | 8.93B | 12.36B | 3.5532 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-26 | Downgrade | HSBC Securities | Hold → Reduce |
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-16-25 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-15-25 | Reiterated | BofA Securities | Buy |
| Dec-15-25 | Reiterated | Goldman | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-10-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Reiterated | BMO Capital Markets | Outperform |
| Oct-14-25 | Upgrade | Erste Group | Hold → Buy |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Eli Lilly Stock (LLY) Opinions on Q1 Earnings and Foundayo Safety Report - Quiver Quantitative
Eli Lilly’s (LLY) Weight Loss Pill is Better Than Novo’s, Says Jim Cramer - Insider Monkey
FDA Reports Liver Failure in Patient Taking Eli Lilly's Foundayo -- Barrons.com - 富途牛牛
Eli Lilly declares $1.73 per share dividend for second quarter By Investing.com - Investing.com Australia
Why Eli Lilly stock is down 3% today: FDA adverse event data explained - Investing.com
RBC Capital reiterates Eli Lilly stock rating on liver safety By Investing.com - Investing.com Canada
$1.73 a share: Lilly fixes May 15 deadline for June payout - Stock Titan
Lilly declares second-quarter 2026 dividend - Benzinga
Is Eli Lilly (LLY) Stock a Buy After the Foundayo FDA Scare? - MEXC
Eli Lilly (LLY) Shares Decline Following FDA Adverse Event Repor - GuruFocus
Eli Lilly tells RBC liver case ‘not reasonably related to Foundayo’ - TipRanks
Eli Lilly (LLY) FDA Adverse Event Report Raises Concerns - GuruFocus
Goldman Sachs reiterates Eli Lilly stock buy rating after FDA report - Investing.com Canada
Bernstein upgrades Eli Lilly stock rating amid liver safety concerns - Investing.com
FDA Reports Liver Failure in Patient Taking Lilly's Foundayo -- Barrons.com - 富途牛牛
Wolfe Research reiterates Eli Lilly stock rating after hepatic safety signal - Investing.com Canada
Barclays raises Eli Lilly stock price target on strong tirzepatide sales - Investing.com Canada
BMO Capital Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,300 - Moomoo
Eli Lilly Just Announced Fantastic News for Shareholders - AOL.com
Jim Cramer Praises Eli Lilly’s Performance - Insider Monkey
Key deals this week: Organon, ARC Resources, Nebius, Eli Lilly and more - MSN
Eli Lilly Bets on Gene Therapy With $2.25 Billion Profluent Deal - thelec.net
Eli Lilly and Company $LLY Stake Boosted by W.G. Shaheen & Associates DBA Whitney & Co - MarketBeat
Eli Lilly (LLY) Valuation Check As GLP 1 Growth And Foundayo Approval Lift Guidance - simplywall.st
Eli Lilly Capitalizes On Consumers' 'Love Affair' With Weight Loss Drugs: Gary Black Says Valuation 'Still Looks Compelling' - Yahoo Finance
Interchange Capital Partners LLC Has $4.62 Million Holdings in Eli Lilly and Company $LLY - MarketBeat
Narwhal Capital Management Sells 2,288 Shares of Eli Lilly and Company $LLY - MarketBeat
Keybank National Association OH Sells 4,443 Shares of Eli Lilly and Company $LLY - MarketBeat
Why Eli Lilly (LLY) Stock Is Trading Up Today - Yahoo Finance UK
ruist Reaffirms Buy on Eli Lilly (LLY) After Trial Success - Insider Monkey
Eli Lilly & Co Soars on Obesity-Drug Power Play - TipRanks
Eli Lilly and Company (NYSE:LLY) Given New $1,133.00 Price Target at Bank of America - MarketBeat
Vest Financial LLC Reduces Stock Position in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly and Company $LLY Position Increased by Wealthfront Advisers LLC - MarketBeat
Citi Sticks to Its Buy Rating for Eli Lilly & Co (LLY) - The Globe and Mail
Comerica Bank Sells 9,402 Shares of Eli Lilly and Company $LLY - MarketBeat
Why Eli Lilly (LLY) Is Up 9.0% After Q1 Beat And Foundayo GLP‑1 LaunchAnd What's Next - simplywall.st
Cadence Bank Sells 1,042 Shares of Eli Lilly and Company $LLY - MarketBeat
Arlington Trust Co LLC Sells 2,113 Shares of Eli Lilly and Company $LLY - MarketBeat
Novo rebrands diabetes pill as Ozempic to tap blockbuster name - ET Manufacturing
Eli Lilly and Company (NYSE:LLY) Rating Increased to Strong-Buy at Wall Street Zen - MarketBeat
Eli Lilly and Company (NYSE:LLY) Shares Unloaded Rep. Lizzie Fletcher - MarketBeat
Eli Lilly Surge Sparks Buzz Amid S&P 500 Index Momentum - Kalkine Media
Lilly Announces Partnership To Develop AI-designed Recombinases For Genetic Medicine - InkFreeNews.com
Eli Lilly (LLY) Faces Slow Start for Foundayo in Weight Loss Mar - GuruFocus
Eli Lilly and Company (NYSE:LLY) Shares Up 3.3% on Earnings Beat - MarketBeat
Stock Quote & Chart | Eli Lilly and Company - investor.lilly.com
LLY Maintains Overweight by Cantor Fitzgerald -- Price Target Ra - GuruFocus
Lilly's Double-Beat Widens the GLP-1 Gap—And a New Pill Could Make It Permanent - MarketBeat
BofA cuts Eli Lilly stock price target on valuation concerns - Investing.com
Raised guidance lifts Eli Lilly stock to fresh highs in strong session - Traders Union
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.32%
0.76%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):